Iovance Biotherapeutics (IOVA) Announces Proposed $500M Common Share Offering

Iovance Biotherapeutics (IOVA) Highlights Updated Clinical Data for Tumor Infiltrating Lymphocyte Therapy Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncologys (ASCO) ASCO20 Virtual Scientific Program.

We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program, said Maria Fardis, Ph.D., President and Chief... More

Iovance Biotherapeutics (IOVA) Prices 16.935M Share Common Offering at $31/Sh

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $525 million. In... More

Iovance Biotherapeutics (IOVA) Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced initial data from pivotal Cohort 4 and updated long-term data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma.

We are very pleased to announce our pivotal Cohort 4 early data from the C-144-01 clinical study in advanced melanoma today, said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. The data from the first 68 patients in Cohort 4, with a 32.4% overall response rate (ORR) at 5.3 months of median study... More